AR040130A1 - Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos - Google Patents
Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicosInfo
- Publication number
- AR040130A1 AR040130A1 ARP030101859A ARP030101859A AR040130A1 AR 040130 A1 AR040130 A1 AR 040130A1 AR P030101859 A ARP030101859 A AR P030101859A AR P030101859 A ARP030101859 A AR P030101859A AR 040130 A1 AR040130 A1 AR 040130A1
- Authority
- AR
- Argentina
- Prior art keywords
- anticopceptive
- esteres
- etonogestrel
- treatment
- gynecological disorders
- Prior art date
Links
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 title 1
- 229960002941 etonogestrel Drugs 0.000 title 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077119 | 2002-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040130A1 true AR040130A1 (es) | 2005-03-16 |
Family
ID=29595014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101859A AR040130A1 (es) | 2002-05-30 | 2003-05-28 | Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7323454B2 (enExample) |
| EP (1) | EP1513861B1 (enExample) |
| JP (1) | JP4716726B2 (enExample) |
| KR (1) | KR20050009723A (enExample) |
| CN (2) | CN1314701C (enExample) |
| AR (1) | AR040130A1 (enExample) |
| AT (1) | ATE349458T1 (enExample) |
| AU (1) | AU2003238081B2 (enExample) |
| BR (1) | BR0311254A (enExample) |
| CA (1) | CA2487722C (enExample) |
| CO (1) | CO5631449A2 (enExample) |
| DE (1) | DE60310714T2 (enExample) |
| DK (1) | DK1513861T3 (enExample) |
| ES (1) | ES2277085T3 (enExample) |
| HR (1) | HRP20041101A2 (enExample) |
| IL (1) | IL165087A0 (enExample) |
| IS (1) | IS2421B (enExample) |
| MX (1) | MXPA04011797A (enExample) |
| NO (1) | NO20044898L (enExample) |
| NZ (1) | NZ536619A (enExample) |
| PE (1) | PE20040068A1 (enExample) |
| PL (1) | PL373855A1 (enExample) |
| PT (1) | PT1513861E (enExample) |
| RS (1) | RS97604A (enExample) |
| RU (1) | RU2325910C2 (enExample) |
| SI (1) | SI1513861T1 (enExample) |
| TW (1) | TW200403065A (enExample) |
| UA (1) | UA80126C2 (enExample) |
| WO (1) | WO2003102012A2 (enExample) |
| ZA (1) | ZA200410410B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200400041A (en) * | 2002-05-30 | 2004-01-01 | Akzo Nobel Nv | Use of new etonogestrel esters |
| ES2691646T3 (es) | 2005-07-15 | 2018-11-28 | Micell Technologies, Inc. | Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada |
| WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
| CA2996768C (en) | 2006-04-26 | 2020-12-08 | Micell Technologies, Inc. | Coatings containing multiple drugs |
| CN101711137B (zh) | 2007-01-08 | 2014-10-22 | 米歇尔技术公司 | 具有可生物降解层的支架 |
| US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
| CA2721832C (en) | 2008-04-17 | 2018-08-07 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
| WO2010009335A1 (en) | 2008-07-17 | 2010-01-21 | Micell Technologies, Inc. | Drug delivery medical device |
| US20100239635A1 (en) | 2009-03-23 | 2010-09-23 | Micell Technologies, Inc. | Drug delivery medical device |
| CN102481195B (zh) | 2009-04-01 | 2015-03-25 | 米歇尔技术公司 | 涂覆支架 |
| EP3366326A1 (en) | 2009-04-17 | 2018-08-29 | Micell Technologies, Inc. | Stents having controlled elution |
| EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | MEDICAL DEVICE DISPENSING MEDICINE |
| EP2531140B1 (en) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
| WO2011133655A1 (en) | 2010-04-22 | 2011-10-27 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
| WO2012009684A2 (en) | 2010-07-16 | 2012-01-19 | Micell Technologies, Inc. | Drug delivery medical device |
| US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
| US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
| CN110269959A (zh) | 2013-03-12 | 2019-09-24 | 脉胜医疗技术公司 | 可生物吸收的生物医学植入物 |
| WO2014186532A1 (en) | 2013-05-15 | 2014-11-20 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
| RU2595818C1 (ru) * | 2015-05-25 | 2016-08-27 | Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" | Способ комплексного лечения дисфункции яичников при применении гормонального контрацептива имплантата "импланона" |
| CN111057120B (zh) * | 2019-12-27 | 2021-04-27 | 苏州翔实医药发展有限公司 | 一种依托孕烯衍生物a及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB845442A (en) | 1956-03-22 | 1960-08-24 | Schering Ag | Manufacture of steroid compounds |
| DE1013284B (de) | 1956-03-22 | 1957-08-08 | Schering Ag | Verfahren zur Einfuehrung der Reste wenig reaktionsfaehiger Carbonsaeuren, insbesondere des ª‰-Cyclopentyl-propionylrestes, in die 17ª‡-staendige Oxygruppe solcher Steroide, die am Kohlenstoffatom 17 neben der Oxygruppe eine Acetylgruppe tragen |
| GB8313921D0 (en) | 1983-05-19 | 1983-06-22 | World Health Org | Contraceptive compositions |
| DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
| DE4240806A1 (de) | 1992-12-01 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol |
| JPH07101884A (ja) | 1993-10-01 | 1995-04-18 | Sanei Gen F F I Inc | 水溶性ヘミセルロースを含有する製剤 |
| CN1135716A (zh) * | 1993-12-27 | 1996-11-13 | 阿克佐诺贝尔公司 | 经皮吸收的药用制剂 |
| WO1997003709A1 (de) | 1995-07-17 | 1997-02-06 | Schering Aktiengesellschaft | Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel |
| DE19613698A1 (de) | 1995-07-17 | 1997-01-23 | Schering Ag | Mittel zur transdermalen Applikation enthaltend Ester des 13-Ethyl-17ß-hydroxy-11-methylen-18,19-dinor-17alpha-pregn-4-en-20-yn-3-ons |
| DE19531936A1 (de) * | 1995-08-17 | 1997-02-20 | Schering Ag | Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend |
| DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
| TR200003743T2 (tr) | 1998-06-19 | 2001-07-23 | Akzo Nobel N.V. | Testosteron türevi. |
| WO1999067270A1 (en) | 1998-06-19 | 1999-12-29 | Akzo Nobel N.V. | Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone) |
| US6180682B1 (en) | 1999-01-26 | 2001-01-30 | Virgil A. Place | Buccal drug delivery system for use in male contraception |
| TW200400041A (en) * | 2002-05-30 | 2004-01-01 | Akzo Nobel Nv | Use of new etonogestrel esters |
-
2003
- 2003-05-19 TW TW092113489A patent/TW200403065A/zh unknown
- 2003-05-22 AT AT03735713T patent/ATE349458T1/de not_active IP Right Cessation
- 2003-05-22 DK DK03735713T patent/DK1513861T3/da active
- 2003-05-22 HR HRP20041101 patent/HRP20041101A2/xx not_active Application Discontinuation
- 2003-05-22 CN CNB038123754A patent/CN1314701C/zh not_active Expired - Fee Related
- 2003-05-22 RU RU2004138807/15A patent/RU2325910C2/ru not_active IP Right Cessation
- 2003-05-22 CA CA2487722A patent/CA2487722C/en not_active Expired - Fee Related
- 2003-05-22 ES ES03735713T patent/ES2277085T3/es not_active Expired - Lifetime
- 2003-05-22 SI SI200330679T patent/SI1513861T1/sl unknown
- 2003-05-22 BR BR0311254-3A patent/BR0311254A/pt not_active IP Right Cessation
- 2003-05-22 RS YU97604A patent/RS97604A/sr unknown
- 2003-05-22 KR KR10-2004-7019330A patent/KR20050009723A/ko not_active Ceased
- 2003-05-22 AU AU2003238081A patent/AU2003238081B2/en not_active Ceased
- 2003-05-22 US US10/516,402 patent/US7323454B2/en not_active Expired - Lifetime
- 2003-05-22 UA UA20041109287A patent/UA80126C2/uk unknown
- 2003-05-22 PL PL03373855A patent/PL373855A1/xx unknown
- 2003-05-22 JP JP2004509703A patent/JP4716726B2/ja not_active Expired - Fee Related
- 2003-05-22 MX MXPA04011797A patent/MXPA04011797A/es active IP Right Grant
- 2003-05-22 CN CNA2007101028610A patent/CN101100480A/zh active Pending
- 2003-05-22 PT PT03735713T patent/PT1513861E/pt unknown
- 2003-05-22 WO PCT/EP2003/050187 patent/WO2003102012A2/en not_active Ceased
- 2003-05-22 NZ NZ536619A patent/NZ536619A/en unknown
- 2003-05-22 DE DE60310714T patent/DE60310714T2/de not_active Expired - Lifetime
- 2003-05-22 EP EP03735713A patent/EP1513861B1/en not_active Expired - Lifetime
- 2003-05-28 AR ARP030101859A patent/AR040130A1/es unknown
- 2003-05-28 PE PE2003000517A patent/PE20040068A1/es not_active Application Discontinuation
-
2004
- 2004-11-08 IL IL16508704A patent/IL165087A0/xx unknown
- 2004-11-10 NO NO20044898A patent/NO20044898L/no not_active Application Discontinuation
- 2004-11-15 IS IS7528A patent/IS2421B/is unknown
- 2004-12-22 CO CO04127949A patent/CO5631449A2/es not_active Application Discontinuation
- 2004-12-23 ZA ZA200410410A patent/ZA200410410B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2001000019A (es) | Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4. | |
| HN1999000124A (es) | Derivados de pirazol substituido. | |
| AR037109A1 (es) | Uso de flibanserina | |
| HN2001000192A (es) | Derivados de pirazol | |
| CR7042A (es) | Indanil aminas aciladas y su uso como farmacos | |
| BR112015018092A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
| ES2170938T3 (es) | Utilizacion del factor neurotrofico derivado de celulas gliales (gdnf) para el tratamiento de las deficiencias auditivas. | |
| UY28150A1 (es) | Agentes terapeuticos | |
| UY27455A1 (es) | Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos. | |
| BR112015018094A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
| HN2005035605A (es) | Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios | |
| BR112015018087A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
| BR112015018089A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
| AR059390A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
| ECSP077296A (es) | Fenilaminotiazoles sustituidos y su uso | |
| HN2001000217A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7 | |
| AR034213A1 (es) | Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv | |
| AR048833A1 (es) | Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos | |
| CR8357A (es) | Derivados de tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorio | |
| CR7610A (es) | Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona | |
| UY27894A1 (es) | Derivados de cinamida. | |
| ECSP045156A (es) | Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6 | |
| PE20040068A1 (es) | Decanoato, undecanoato y dodecanoato de etonogestrel | |
| ATE347358T1 (de) | Schwimmende orale formulierungen mit kontrollierter freisetzung von betain | |
| AR053775A1 (es) | Nonadepsipeptidos acilados ii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |